Loading
ETX-636 is an experimental small molecule from Ensem Therapeutics, in phase 2 trials for advanced breast cancer and advanced solid tumours.
ETX-636 is a small molecule (oral tablet) from Ensem Therapeutics. An allosteric, pan-mutant-selective PI3K-alpha inhibitor and degrader, which the company says targets mutant PI3K-alpha without affecting glucose homeostasis. Its furthest stage is phase 2, for advanced breast cancer and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06993844, recruiting, started 10 June 2025; FDA Fast Track for advanced breast cancer (Oct 2025); first patient dosed in China Feb 2026 (Ensem news list). Whether it works in people has not been established unless a trial below reports it.
An allosteric, pan-mutant-selective PI3K-alpha inhibitor and degrader, which the company says targets mutant PI3K-alpha without affecting glucose homeostasis. Connects to PIK3CA / PI3K-alpha.
1.ETX-636 slips into a pocket on PIK3CA / PI3K-alpha.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ETX-636" OR ABSTRACT:"ETX-636") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETX-636, not a curated reading list.
Shares Ensem Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares PIK3CA / PI3K-alpha, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PIK3CA / PI3K-alpha, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares Ensem Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/